Evercore ISI Reaffirms Buy Rating on Insmed Incorporated
Evercore ISI Group maintains its buy rating for Insmed with a $160 price target, a 54.65% upside from the current price.
Key Points
- Evercore ISI Group reiterated its buy rating for Insmed Incorporated (INSM) with a price target of $160 on June 22, 2026.
- Evercore ISI Group's $160 price target implies 54.65% upside from Insmed Incorporated's ($INSM) current $103.46 share price.
- Shares of NasdaqGS:INSM traded near $95.8 on Monday, with a market cap of $20.76 billion and a forward P/E ratio of 377.1.
- Major institutional players like JPMorgan and BlackRock adjusted their positions in Insmed, showing varying levels of confidence.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Evercore ISI Group has reiterated its buy rating on Insmed Incorporated, traded as INSM on the NasdaqGS. Analyst Josh Schimmer set a price target of $160 for the biotechnology company on June 22, 2026. This reaffirmation comes as Insmed continues to advance its pipeline of therapies for serious and rare diseases.
Evercore ISI Group vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Insmed Incorporated
JPMorgan Chase & Co increased its holdings in Insmed by 950,987 shares, bringing its total to 24,150,499 shares worth roughly $3.70 billion. BlackRock, Inc. also grew its position by 1,613,094 shares, ending with 16,678,146 shares valued at about $2.73 billion, reflecting a 10.7% increase. Meanwhile, Darwin Global Management, Ltd. reduced its stake by 4,128,093 shares, now holding 16,805,184 shares worth around $2.58 billion, marking a 19.7% decrease. FMR LLC increased its holdings by 3,232,231 shares, totaling 13,160,167 shares valued at approximately $2.15 billion, a 32.6% rise. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions in Insmed.
Insmed Incorporated Stock Down 12.7%
Shares of NasdaqGS:INSM traded near $95.8 on Monday. Insmed has a market capitalization of about $20.76 billion and a forward P/E ratio of 377.1, indicating a high valuation relative to its earnings. The stock has a 52-week low of $90.39 and a high of $212.75. Its 50-day moving average is $119.39, while the 200-day moving average stands at $153.58. The company has a current ratio of 4.47, a quick ratio of 3.88, and a debt-to-equity ratio of 105.34.
$INSM price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Insmed reported revenue of $819.56 million, reflecting a modest growth rate of 2.3%. However, the company is not currently profitable, with a net margin of -144.4% and a return on equity of -294.5%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Insmed Incorporated
On June 8, 2026, Chair and CEO William Lewis sold 6,515 shares at an average price of $94.03 under a planned sale. Chief Medical Officer Martina Flammer sold 1,858 shares at an average price of $103.78 on June 5, also as part of a planned sale. Additionally, on June 3, non-planned sales included 7,605 shares by William Lewis, 2,159 shares by Chief Legal Officer Michael Alexander Smith, 2,370 shares by Chief Operating Officer Roger Adsett, and 2,404 shares by Chief Financial Officer Sara Bonstein, all at an average price of $102.27.
Analysts Set New Price Targets
On June 22, 2026, Evercore ISI Group maintained its buy rating for Insmed with a $160 price target. Other firms have also shown confidence, with JP Morgan setting a $179 target on June 8 and RBC Capital maintaining a $195 target on June 5. The consensus among 21 analysts is a strong buy, with an average target price of $197.14.
About Insmed Incorporated
Insmed Incorporated is a biotechnology company based in Bridgewater, New Jersey. It develops therapies for serious and rare diseases, including treatments for lung infections and other conditions. The company is led by CEO William H. Lewis and employs 1,664 people. Insmed's pipeline includes products in various stages of clinical trials, focusing on innovative approaches to unmet medical needs.
Bottom Line
Evercore ISI's reaffirmation of its buy rating for Insmed signals continued confidence in the company's prospects. With a robust pipeline and ongoing clinical trials, Insmed remains a key player in the biotechnology sector. As always, remember that 13F filings and analyst ratings are backward-looking and may not reflect current positions or opinions.
Get Insmed Incorporated alerts
New 13F filings, insider trades, and analyst moves on $INSM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.